COMET trial: active monitoring is a viable option for some patients with low-risk DCIS

Intervista a E. Shelley Hwang By 12 Dicembre 2024No Comments
Dai congressi

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at SABCS 2024. We interviewed E. Shelley Hwang (Mary and Deryl Hart Distinguished Professor of Surgery, Vice-Chair of Research in the Department of Surgery, and a Professor of Radiology at the Duke University School of Medicine, Durham) at the congress of San Antonio.